IN2014CN03130A - - Google Patents
Info
- Publication number
- IN2014CN03130A IN2014CN03130A IN3130CHN2014A IN2014CN03130A IN 2014CN03130 A IN2014CN03130 A IN 2014CN03130A IN 3130CHN2014 A IN3130CHN2014 A IN 3130CHN2014A IN 2014CN03130 A IN2014CN03130 A IN 2014CN03130A
- Authority
- IN
- India
- Prior art keywords
- represent
- npt
- preventive
- formula
- iib
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
- C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
- C07F9/655354—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Abstract
The objective of the present invention is to provide a compound having inhibitory activity against an intestinal phosphate transporter (NPT IIb) and useful as an active ingredient in a hyperphosphatemia therapeutic agent and/or preventive. A thiophene compound represented by formula (I) may be used as a hyperphosphatemia therapeutic agent and/or preventive having NPT IIb inhibitory activity. (In the formula R each represent H or a lower alkyl or the like L each represent a lower alkyl or the like X represents CH or O X each represent CH or N k is 1 3 and n is 0 1.)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011236533 | 2011-10-27 | ||
PCT/JP2012/077660 WO2013062065A1 (en) | 2011-10-27 | 2012-10-25 | Aminoalkyl-substituted n-thienyl benzamide derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03130A true IN2014CN03130A (en) | 2015-07-03 |
Family
ID=48167891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3130CHN2014 IN2014CN03130A (en) | 2011-10-27 | 2012-10-25 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9062032B2 (en) |
EP (1) | EP2772490B1 (en) |
JP (2) | JP2013107880A (en) |
KR (1) | KR101941048B1 (en) |
CN (1) | CN103906741B (en) |
AR (1) | AR088563A1 (en) |
AU (1) | AU2012329913A1 (en) |
CA (1) | CA2853688C (en) |
EA (1) | EA023955B1 (en) |
ES (1) | ES2585415T3 (en) |
IL (1) | IL232230A0 (en) |
IN (1) | IN2014CN03130A (en) |
MX (1) | MX342521B (en) |
PL (1) | PL2772490T3 (en) |
TW (1) | TW201323419A (en) |
WO (1) | WO2013062065A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3150582A1 (en) | 2012-10-02 | 2017-04-05 | Gilead Sciences, Inc. | Inhibitors of histone demethylases |
US9499553B2 (en) | 2013-03-13 | 2016-11-22 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same |
SI2975030T1 (en) | 2013-03-13 | 2020-10-30 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative |
TWI594975B (en) * | 2013-04-24 | 2017-08-11 | 第一三共股份有限公司 | Compound having di-carboxylic moiety |
SG11201600891UA (en) | 2013-08-08 | 2016-03-30 | Galapagos Nv | Thieno[2,3-c]pyrans as cftr modulators |
WO2015064532A1 (en) * | 2013-10-30 | 2015-05-07 | 第一三共株式会社 | Morpholine compound |
WO2015153498A1 (en) * | 2014-03-31 | 2015-10-08 | Epitherapeutics, Aps | Inhibitors of histone demethylases |
WO2016026372A1 (en) * | 2014-08-22 | 2016-02-25 | 江苏恒瑞医药股份有限公司 | Thienocycloalkyl or thienoheterocyclic derivatives, preparation method thereof and use thereof in medicine |
CN107072993B (en) | 2014-09-12 | 2021-02-12 | 中外制药株式会社 | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor |
ES2864277T3 (en) | 2014-09-26 | 2021-10-13 | Daiichi Sankyo Co Ltd | Salt of dicarboxylic acid compounds |
CN105524053B (en) * | 2014-10-19 | 2020-06-05 | 广东东阳光药业有限公司 | Tetrahydrobenzothiophene compounds |
TW201700458A (en) | 2015-04-24 | 2017-01-01 | 第一三共股份有限公司 | Method for producing dicarboxylic acid compound |
CN107082773B (en) * | 2016-02-16 | 2020-07-28 | 江苏恒瑞医药股份有限公司 | Sulfate of intestinal 2B type sodium phosphate cotransporter inhibitor and crystal form thereof |
ES2830444T3 (en) * | 2016-08-15 | 2021-06-03 | Lilly Co Eli | Condensed thiophene derivatives useful as NaPi-IIb inhibitors |
JOP20190080A1 (en) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof |
CN109422723B (en) * | 2017-08-25 | 2021-02-23 | 江苏恒瑞医药股份有限公司 | Crystal form of intestinal 2B type sodium phosphate cotransporter inhibitor and preparation method thereof |
CA3221186A1 (en) | 2021-06-08 | 2022-12-15 | Kenichi Sakai | Formulation containing dihydropyridazine-3,5-dione derivative |
AR126060A1 (en) | 2021-06-08 | 2023-09-06 | Chugai Pharmaceutical Co Ltd | METHOD FOR PRODUCING DIHYDROPYRIDAZIN-3,5-DIONE DERIVATIVE |
WO2023203254A2 (en) | 2022-04-22 | 2023-10-26 | Fundamental Pharma Gmbh | Effective means to modulate nmda receptor-mediated toxicity |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002213048A1 (en) | 2000-10-05 | 2002-04-15 | Smith Kline Beecham Corporation | Phosphate transport inhibitors |
JP2007131532A (en) * | 2001-09-28 | 2007-05-31 | Kirin Brewery Co Ltd | Compound for inhibiting delivery of phosphorus in living body and drug containing the same |
JPWO2003048134A1 (en) | 2001-12-05 | 2005-04-14 | 日本たばこ産業株式会社 | Triazole compounds and pharmaceutical use thereof |
EP1614676A4 (en) | 2003-03-27 | 2009-03-25 | Kirin Pharma Kk | Compound inhibiting in vivo phosphorus transport and medicine containing the same |
WO2006093518A2 (en) | 2004-06-25 | 2006-09-08 | Apath, Llc | Thienyl compounds for treating virus-related conditions |
CA2579089A1 (en) | 2004-08-30 | 2006-03-09 | Government Of The United States Of America As Represented By The Secreta Ry Department Of Health And Human Services | Inhibition of viruses using rnase h inhibitors |
WO2006044826A2 (en) | 2004-10-20 | 2006-04-27 | Compass Pharmaceuticals Llc | Thiophens and their use as anti-tumor agents |
KR101343399B1 (en) * | 2008-01-08 | 2013-12-19 | 퍼듀 퍼머 엘피 | Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
JP5617919B2 (en) | 2010-04-28 | 2014-11-05 | アステラス製薬株式会社 | Tetrahydrobenzothiophene compound |
JP5823514B2 (en) | 2010-07-07 | 2015-11-25 | アーデリクス,インコーポレーテッド | Compounds and methods for inhibiting phosphate transport |
WO2012006473A1 (en) | 2010-07-07 | 2012-01-12 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590965B1 (en) | 2010-07-07 | 2016-04-20 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2590510B1 (en) | 2010-07-07 | 2016-09-28 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
EP2591354B1 (en) | 2010-07-07 | 2016-09-07 | Ardelyx, Inc. | Compounds and methods for inhibiting phosphate transport |
-
2012
- 2012-10-25 EA EA201490875A patent/EA023955B1/en not_active IP Right Cessation
- 2012-10-25 AU AU2012329913A patent/AU2012329913A1/en not_active Abandoned
- 2012-10-25 WO PCT/JP2012/077660 patent/WO2013062065A1/en active Application Filing
- 2012-10-25 KR KR1020147014256A patent/KR101941048B1/en active IP Right Grant
- 2012-10-25 CN CN201280053147.6A patent/CN103906741B/en active Active
- 2012-10-25 MX MX2014005090A patent/MX342521B/en active IP Right Grant
- 2012-10-25 EP EP12844048.4A patent/EP2772490B1/en active Active
- 2012-10-25 JP JP2012236135A patent/JP2013107880A/en active Pending
- 2012-10-25 PL PL12844048.4T patent/PL2772490T3/en unknown
- 2012-10-25 ES ES12844048.4T patent/ES2585415T3/en active Active
- 2012-10-25 CA CA2853688A patent/CA2853688C/en active Active
- 2012-10-25 IN IN3130CHN2014 patent/IN2014CN03130A/en unknown
- 2012-10-25 JP JP2013540835A patent/JP6020460B2/en active Active
- 2012-10-25 TW TW101139423A patent/TW201323419A/en unknown
- 2012-10-25 US US14/354,086 patent/US9062032B2/en active Active
- 2012-10-26 AR ARP120104035A patent/AR088563A1/en unknown
-
2014
- 2014-04-24 IL IL232230A patent/IL232230A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA201490875A1 (en) | 2014-09-30 |
WO2013062065A1 (en) | 2013-05-02 |
BR112014010169A2 (en) | 2017-04-25 |
MX342521B (en) | 2016-10-03 |
CA2853688C (en) | 2018-06-12 |
PL2772490T3 (en) | 2016-11-30 |
JP2013107880A (en) | 2013-06-06 |
KR101941048B1 (en) | 2019-01-22 |
KR20140096322A (en) | 2014-08-05 |
MX2014005090A (en) | 2015-02-12 |
CN103906741B (en) | 2016-01-20 |
EP2772490A1 (en) | 2014-09-03 |
US9062032B2 (en) | 2015-06-23 |
US20150031727A1 (en) | 2015-01-29 |
IL232230A0 (en) | 2014-06-30 |
EP2772490A4 (en) | 2015-01-21 |
TW201323419A (en) | 2013-06-16 |
JP6020460B2 (en) | 2016-11-02 |
EA023955B1 (en) | 2016-07-29 |
JPWO2013062065A1 (en) | 2015-04-02 |
CA2853688A1 (en) | 2013-05-02 |
AR088563A1 (en) | 2014-06-18 |
AU2012329913A1 (en) | 2014-05-22 |
ES2585415T3 (en) | 2016-10-05 |
EP2772490B1 (en) | 2016-04-06 |
CN103906741A (en) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03130A (en) | ||
IN2015MN00405A (en) | ||
TN2011000400A1 (en) | Inhibitors of beta-secretase | |
BR112014017749A8 (en) | 3,5-DISUBSTITUTED ALKYNYLBENZENE COMPOUND AND SALT THEREOF | |
MX356342B (en) | Endoparasite control agent and use thereof. | |
MX348422B (en) | Inhibitors of arginase and their therapeutic applications. | |
MX336381B (en) | Boronates as arginase inhibitors. | |
IN2014CN00712A (en) | ||
MX2013001805A (en) | 2-(arylamino)-3h-imidazo[4,5-b]pyridine-6-carboxamide derivatives and their use as mpges-1 inhibitors. | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
CL2009000650A1 (en) | Compounds derived from amino-pyrazine, kinase-pi 3 inhibitors; pharmaceutical composition; and use for the treatment of inflammatory or allergic conditions, such as respiratory diseases, rheumatoid arthritis, ulcerative colitis, among others. | |
TN2015000245A1 (en) | Heterocyclic compound | |
GEP20146197B (en) | New compounds | |
EA201291121A1 (en) | TETRAHYDROBENZOTIOPHEN COMPOUNDS | |
MX351812B (en) | Pyridone derivative. | |
MA35402B1 (en) | Pesticide compositions and related processes | |
UA108926C2 (en) | LibreOfficeKINASE PYRROLO[2,3-DEPENDENT INHIBITORS | |
MY172924A (en) | Neprilysin inhibitors | |
AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
IN2014CN04204A (en) | ||
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
IN2012DN02502A (en) | ||
IN2014CN04449A (en) | ||
IN2013CN01335A (en) |